TSEN34: A Potential Drug Target and Biomarker for Leukocyte Receptor Cluster (LRC) Member 5

Target Name: TSEN34

NCBI ID: G79042

TSEN34

TSEN34: A Potential Drug Target and Biomarker for Leukocyte Receptor Cluster (LRC) Member 5

Introduction

Leukocyte receptor cluster (LRC) member 5, also known as TSEN34, is a non-coding RNA molecule that plays a crucial role in the regulation of hematopoietic stem cell (HSC) proliferation and differentiation. HSC is a stem cell that gives rise to all blood cells, including red blood cells, white blood cells, and platelets. The LRC is a protein complex that consists of several non-coding RNAs, including TSEN34. The LRC is involved in the development, maintenance, and function of HSC, and it has been implicated in various diseases, including leukemia, infections, and inflammation.

TSEN34 functions as a negative regulator of the LRC, specifically, it binds to the protein activator of the LRC, PDZL1, and inhibits its activity. PDZL1 is a transcription factor that plays a crucial role in the development and maintenance of the LRC. TSEN34 inhibits PDZL1 by binding to its N-terminal region, which prevents PDZL1 from binding to its C-terminal region and activating its gene expression.

The inhibition of PDZL1 by TSEN34 is critical for the maintenance of normal hematopoietic stem cell proliferation and differentiation. HSCs are self-replicating cells that can differentiate into all blood cell types. When HSCs differentiate into blood cells, they undergo a process called maturation, during which they undergo a series of signaling pathways that determine the specific cell type that will be produced. The LRC plays a critical role in these signaling pathways, as it regulates the interactions between the signaling molecules that are involved in the maturation process.

TSEN34 is a key regulator of the LRC, and its dysfunction has been implicated in various diseases, including leukemia. Leukemia is a type of cancer that affects the bone marrow, where HSCs are produced. In leukemia, the LRC is disrupted, and there is an increased production of leukemia-promoting cells. This is because of the loss of normal cell-cycle regulation, which leads to the rapid proliferation of cancer cells.

TSEN34 has also been implicated in the regulation of infections, including bacterial and viral infections. Bacteria and viruses have the ability to infect the body and cause disease. The LRC plays a critical role in the regulation of the immune response, as it regulates the interactions between the signaling molecules that are involved in the immune response. TSEN34 has been shown to play a role in the regulation of the production of T-cells, which are the key immune cells that are involved in the fight against bacterial and viral infections.

In addition to its role in the regulation of HSC proliferation and differentiation, TSEN34 has also been shown to play a role in the regulation of the development and progression of cancer. Cancer is a disease that is characterized by the loss of control over cell growth and division. TSEN34 has been shown to play a role in the regulation of cell-cycle progression, as it has been shown to inhibit the activity of the protein kinase cyclin D1. This protein kinase is involved in the regulation of cell-cycle progression, and its dysfunction has been implicated in the development and progression of cancer.

TSEN34 has also been shown to play a role in the regulation of inflammation. Inflammation is a critical immune response that helps to protect the body against infections and injuries. TSEN34 has also been shown to play a role in the regulation of the production of pro-inflammatory cytokines, which are involved in the inflammatory response. This is

Protein Name: TRNA Splicing Endonuclease Subunit 34

Functions: Constitutes one of the two catalytic subunit of the tRNA-splicing endonuclease complex, a complex responsible for identification and cleavage of the splice sites in pre-tRNA. It cleaves pre-tRNA at the 5'- and 3'-splice sites to release the intron. The products are an intron and two tRNA half-molecules bearing 2',3'-cyclic phosphate and 5'-OH termini. There are no conserved sequences at the splice sites, but the intron is invariably located at the same site in the gene, placing the splice sites an invariant distance from the constant structural features of the tRNA body. It probably carries the active site for 3'-splice site cleavage. The tRNA splicing endonuclease is also involved in mRNA processing via its association with pre-mRNA 3'-end processing factors, establishing a link between pre-tRNA splicing and pre-mRNA 3'-end formation, suggesting that the endonuclease subunits function in multiple RNA-processing events

The "TSEN34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TSEN34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets